An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue.

TitleAn endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue.
Publication TypeJournal Article
Year of Publication2002
AuthorsHuang J, Kirk B, Favis R, Soussi T, Paty P, Cao W, Barany F
Date Published2002 Mar 14
KeywordsAdenocarcinoma, Base Sequence, Biosensing Techniques, Colorectal Neoplasms, Deoxyribonuclease (Pyrimidine Dimer), DNA Ligases, DNA Mutational Analysis, DNA Primers, DNA, Neoplasm, Endodeoxyribonucleases, Gene Deletion, Genes, ras, Genes, Tumor Suppressor, Humans, Molecular Sequence Data, Mutation, Polymerase Chain Reaction, Sensitivity and Specificity

Knowledge of inherited and sporadic mutations in known and candidate cancer genes may influence clinical decisions. We have developed a mutation scanning method that combines thermostable EndonucleaseV (Endo V) and DNA ligase. Variant and wild-type PCR amplicons are generated using fluorescently labeled primers, and heteroduplexed. Thermotoga maritima (Tma) EndoV recognizes and primarily cleaves heteroduplex DNA one base 3' to the mismatch, as well as nicking matched DNA at low levels. Thermus species (Tsp.) AK16D DNA ligase reseals the background nicks to create a highly sensitive and specific assay. The fragment mobility on a DNA sequencing gel reveals the approximate position of the mutation. This method identified 31/35 and 8/8 unique point mutations and insertions/deletions, respectively, in the p53, VHL, K-ras, APC, BRCA1, and BRCA2 genes. The method has the sensitivity to detect K-ras mutations diluted 1 : 20 with wild-type DNA, a p53 mutation in a 1.7 kb amplicon, and unknown p53 mutations in pooled DNA samples. EndoV/Ligase mutation scanning combined with PCR/LDR/Universal array proved superior to automated DNA sequencing for detecting p53 mutations in colon tumors. This technique is well suited for scanning low-frequency mutations in pooled samples and for analysing tumor DNA containing a minority of the unknown mutation.

Alternate JournalOncogene
PubMed ID11896624
Grant ListP01-CA65930 / CA / NCI NIH HHS / United States
R01-CA81467 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587